| Jonathan Meltzer, | |
|
397 Willis Ave, Williston Park, NY 11596-2208 | |
| (516) 739-5503 | |
| Not Available |
| Full Name | Jonathan Meltzer |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 4 Years |
| Location | 397 Willis Ave, Williston Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770185613 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Professional Occupational And Physical Therapy Pllc | 3779873401 | 518 |
News Archive
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
A lifestyle intervention incorporating exercise training and diet counseling in primary health care settings appears to improve quality of life among adults at moderate to high risk for heart disease and appears cost-effective compared to standard care, according to a report in the September 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
U-Systems announced today that Community Hospital of the Monterey Peninsula's Breast Care Center has initiated participation in the SOMO·INSIGHT Clinical Study.
› Verified 1 days ago
| Provider Name | Professional Occupational & Physical Therapy Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1205296902 PECOS PAC ID: 3779873401 Enrollment ID: O20160608000715 |
News Archive
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
A lifestyle intervention incorporating exercise training and diet counseling in primary health care settings appears to improve quality of life among adults at moderate to high risk for heart disease and appears cost-effective compared to standard care, according to a report in the September 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
U-Systems announced today that Community Hospital of the Monterey Peninsula's Breast Care Center has initiated participation in the SOMO·INSIGHT Clinical Study.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Meltzer, 576 Broadhollow Rd, Melville, NY 11747-5002 Ph: (631) 359-5859 | Jonathan Meltzer, 397 Willis Ave, Williston Park, NY 11596-2208 Ph: (516) 739-5503 |
News Archive
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
A lifestyle intervention incorporating exercise training and diet counseling in primary health care settings appears to improve quality of life among adults at moderate to high risk for heart disease and appears cost-effective compared to standard care, according to a report in the September 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
U-Systems announced today that Community Hospital of the Monterey Peninsula's Breast Care Center has initiated participation in the SOMO·INSIGHT Clinical Study.
› Verified 1 days ago
Dr. Vinod Singh, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 23 Hillside Ave, Williston Park, NY 11596 Phone: 516-307-1515 Fax: 516-307-1514 | |
Professional Occupational & Physical Therapy, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 397 Willis Ave, Williston Park, NY 11596 Phone: 516-739-5503 Fax: 516-739-5565 | |
Mrs. Sherin Cheriyan Mathew, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 195 Cornwell Ave, Williston Park, NY 11596 Phone: 516-385-1354 | |
Ashley Michele Willoughby, Physical Therapist Medicare: Medicare Enrolled Practice Location: 397 Willis Ave, Williston Park, NY 11596 Phone: 516-862-2671 Fax: 516-858-3712 | |
Joseph Vincent D'auria, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 476 Nassau Blvd, Williston Park, NY 11596 Phone: 917-612-3086 | |
Nalini K Sheth, B.S. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 257 Cornwell Ave, Williston Park, NY 11596 Phone: 516-294-6126 | |
Maureen Ann Camizzi Kirschner, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 623 Concord Ave, Williston Park, NY 11596 Phone: 516-873-8870 Fax: 516-873-8870 |